Phase 3 HER2CLIMB-05 trial demonstrates a 35.9% reduction in risk of disease progression or death with maintenance tucatinib combination.
Officials say low vaccination rates in rural communities are fueling the spread of the highly contagious virus.
Nearly 1 in 3 patients with systemic lupus erythematosus (SLE) are taking a supplement–medication combination with potential for an interaction, according to ...
The approval makes remibrutinib the first targeted therapy approved for symptomatic dermographism, expanding its indication beyond chronic spontaneous urticaria.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results